MA53732A - Anticorps dirigés contre bcma soluble - Google Patents
Anticorps dirigés contre bcma solubleInfo
- Publication number
- MA53732A MA53732A MA053732A MA53732A MA53732A MA 53732 A MA53732 A MA 53732A MA 053732 A MA053732 A MA 053732A MA 53732 A MA53732 A MA 53732A MA 53732 A MA53732 A MA 53732A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies against
- soluble bcma
- against soluble
- bcma
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862738997P | 2018-09-28 | 2018-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53732A true MA53732A (fr) | 2022-01-05 |
Family
ID=68296657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053732A MA53732A (fr) | 2018-09-28 | 2019-09-27 | Anticorps dirigés contre bcma soluble |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11505614B2 (fr) |
| EP (1) | EP3856781A1 (fr) |
| JP (1) | JP2022501389A (fr) |
| KR (1) | KR20210068408A (fr) |
| CN (1) | CN112703204A (fr) |
| AR (1) | AR116548A1 (fr) |
| BR (1) | BR112021005669A2 (fr) |
| MA (1) | MA53732A (fr) |
| TW (1) | TW202028239A (fr) |
| UY (1) | UY38393A (fr) |
| WO (1) | WO2020069303A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3819007A1 (fr) * | 2019-11-11 | 2021-05-12 | Amgen Research (Munich) GmbH | Régime de dosage pour agents anti-bcma |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1985A (en) | 1841-02-18 | Charles m | ||
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (fr) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Récepteurs chimériques par liaison et expression de l'ADN |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| EP0307434B2 (fr) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Anticorps alteres |
| ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0402226A1 (fr) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Vecteurs de transformation de la levure yarrowia |
| US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
| CA2105984C (fr) | 1991-03-11 | 2002-11-26 | Milton J. Cormier | Clonage et expression de la luciferase de renilla |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
| KR960705209A (ko) | 1993-09-10 | 1996-10-09 | 잭 엠. 그랜노위츠 | 녹색 형광 단백의 용도 |
| WO1995021191A1 (fr) | 1994-02-04 | 1995-08-10 | William Ward | Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte |
| US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
| CA2219361C (fr) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Anticorps humains derives d'une xenosouris immunisee |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
| US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
| US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| EP2305027B1 (fr) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Mammifères trangèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus. |
| JP3795533B2 (ja) | 1996-12-12 | 2006-07-12 | プロルーム・リミテツド | 感染性物質を検出及び同定するための方法及び装置 |
| EP1064360B1 (fr) | 1998-03-27 | 2008-03-05 | Prolume, Ltd. | Luciferases, proteines fluorescentes gfp, leurs acides nucleiques, et leur utilisation en diagnostic |
| TR200003087T2 (tr) | 1998-04-21 | 2001-02-21 | Micromet Ag | Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları |
| GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
| ATE251181T1 (de) | 1998-07-28 | 2003-10-15 | Micromet Ag | Heterominikörper |
| BRPI0415457A (pt) | 2003-10-16 | 2006-12-05 | Micromet Ag | constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo |
| EP1753783B1 (fr) | 2004-06-03 | 2014-08-06 | Novimmune SA | Anticorps anti-cd3 et leurs methodes d'utilisation |
| PL2520590T3 (pl) | 2007-04-03 | 2019-02-28 | Amgen Research (Munich) Gmbh | Domena wiążąca wykazująca krzyżową swoistość gatunkową |
| EP3375790A1 (fr) | 2008-10-01 | 2018-09-19 | Amgen Research (Munich) GmbH | Anticorps bispécifique à chaîne unique à domaine unique particulière d'une espèce à l'autre |
| WO2013026837A1 (fr) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t. |
| PL3321286T3 (pl) | 2011-08-23 | 2021-05-31 | Roche Glycart Ag | Dwuswoiste cząsteczki wiążące antygen aktywujące limfocyty T |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| CA2903258C (fr) | 2013-03-15 | 2019-11-26 | Amgen Inc. | Anticorps heterodimeres bispecifiques |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
| US20160257748A1 (en) | 2013-09-25 | 2016-09-08 | Amgen Inc. | V-c-fc-v-c antibody |
| EP3029068A1 (fr) * | 2014-12-03 | 2016-06-08 | EngMab AG | Anticorps bispécifiques contre du CD3epsilon et BCMA pour utilisation dans le traitement de maladies |
| WO2017083511A1 (fr) | 2015-11-13 | 2017-05-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Polypeptides et protéines anti-bcma |
| JP7011600B2 (ja) * | 2016-01-12 | 2022-01-26 | ジェイムズ リチャード ベレンソン， | 被験体の免疫状態をモニタリングするための改善された方法 |
| DK3411402T3 (da) | 2016-02-03 | 2022-02-07 | Amgen Res Munich Gmbh | Bcma- og cd3-bispecifikke t-celle-engagerende antistofkonstruktioner |
-
2019
- 2019-09-27 UY UY0001038393A patent/UY38393A/es unknown
- 2019-09-27 CN CN201980056983.1A patent/CN112703204A/zh active Pending
- 2019-09-27 AR ARP190102761A patent/AR116548A1/es unknown
- 2019-09-27 MA MA053732A patent/MA53732A/fr unknown
- 2019-09-27 US US16/585,318 patent/US11505614B2/en active Active
- 2019-09-27 BR BR112021005669-6A patent/BR112021005669A2/pt unknown
- 2019-09-27 WO PCT/US2019/053433 patent/WO2020069303A1/fr active Search and Examination
- 2019-09-27 TW TW108135221A patent/TW202028239A/zh unknown
- 2019-09-27 EP EP19790922.9A patent/EP3856781A1/fr active Pending
- 2019-09-27 JP JP2021516763A patent/JP2022501389A/ja active Pending
- 2019-09-27 KR KR1020217008023A patent/KR20210068408A/ko active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| US11505614B2 (en) | 2022-11-22 |
| EP3856781A1 (fr) | 2021-08-04 |
| CN112703204A (zh) | 2021-04-23 |
| TW202028239A (zh) | 2020-08-01 |
| UY38393A (es) | 2020-03-31 |
| JP2022501389A (ja) | 2022-01-06 |
| KR20210068408A (ko) | 2021-06-09 |
| BR112021005669A2 (pt) | 2021-06-22 |
| WO2020069303A1 (fr) | 2020-04-02 |
| AR116548A1 (es) | 2021-05-19 |
| US20200102398A1 (en) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR21C1030I2 (fr) | Conjugué anticorps anti-her2-médicament | |
| MA49823A (fr) | Anticorps dirigés contre pd-l1 | |
| MA47694A (fr) | Anticorps anti-tigit | |
| MA49034A (fr) | Anticorps anti-lag3 | |
| MA51447A (fr) | Conjugué anticorps monoclonal-médicament dirigé contre bcma | |
| MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
| MA46057A (fr) | Anticorps anti-ctla4 | |
| MA47268A (fr) | Anticorps anti-gpc3 | |
| MA53434A (fr) | Anticorps anti-tigit | |
| MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
| MA52884A (fr) | Anticorps anti-il-11 | |
| MA46041A (fr) | Anticorps anti-tim -3 | |
| DK3592393T3 (da) | Frigørbare konjugater | |
| MA45784A (fr) | Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps | |
| MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
| MA45672A (fr) | Anticorps multispécifiques dirigés contre cd40 et cd137 | |
| MA50352A (fr) | Anticorps multispécifiques | |
| MA47472A (fr) | Anticorps | |
| MA49863A (fr) | Anticorps dirigés contre la mort programmée 1 (pd -1) | |
| MA53297A (fr) | Anticorps anti-icos | |
| MA49749A (fr) | Anticorps anti-cd137 | |
| MA52366A (fr) | Anticorps anti-tl1a optimisés | |
| MA42843A (fr) | Anticorps anti-cd115 | |
| MA51134A (fr) | Anticorps anti-alpha-synucléine | |
| DK3668874T3 (da) | Pyrrolobenzodiazepin-konjugater |